Company Analysis
Sign in

Spero Therapeutics, Inc. (SPRO)

Nasdaq: SPRO · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2017
Full chart Alerts Compare
Grade6.1
◀ Past 5.8● Present 6.5▶ Future 6.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

7 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Spero Therapeutics, Inc.’s names, not what it holds today.

Patents granted
7
7 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 3 in 2024 and 1 in 2023
Applications published
13
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
SPERO THERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
0 granted
13 published
SPERO THERAPEUTICS, INC. its own name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in GB)
7 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Feb 18, 202512,226,403Tebipenem pivoxil immediate and modified release oral dosage formsPharmaceuticalsSPERO THERAPEUTICS, INC.
Nov 19, 202412,146,004Polymyxin compounds and uses thereofPharmaceuticalsSPERO THERAPEUTICS, INC.
Sep 24, 202412,098,155Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of usePharmaceuticalsSPERO THERAPEUTICS, INC.
Jul 30, 202412,048,691High dosage tebipenem pivoxil tablet formulationPharmaceuticalsSPERO THERAPEUTICS, INC.
Aug 8, 202311,718,621Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of usePharmaceuticalsSPERO THERAPEUTICS, INC.
Oct 4, 202211,459,357Polymyxin compoundsPharmaceuticalsSPERO THERAPEUTICS, INC.
Jan 12, 202110,889,587Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of usePharmaceuticalsSPERO THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Feb 13, 20252025/0051334TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USEPharmaceuticalsSPERO THERAPEUTICS, INC.
Feb 13, 20252025/0049766HIGH DOSAGE TEBIPENEM PIVOXIL TABLET FORMULATIONPharmaceuticalsSPERO THERAPEUTICS, INC.
Jan 9, 20252025/0009718TEBIPENEM PIVOXIL IMMEDIATE AND MODIFIED RELEASE ORAL DOSAGE FORMSPharmaceuticalsSPERO THERAPEUTICS, INC.
Nov 7, 20242024/0366599HUMAN EFFICACIOUS DOSE AND DOSAGE SCHEDULE OF SPR720PharmaceuticalsSPERO THERAPEUTICS, INC.
Oct 19, 20232023/0331728TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USEPharmaceuticalsSPERO THERAPEUTICS, INC. · patent 12,098,155 granted from it
Oct 12, 20232023/0322858POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICSPharmaceuticalsSPERO THERAPEUTICS, INC.
Jan 12, 20232023/0012121COMPOUNDSPharmaceuticalsSPERO THERAPEUTICS, INC.
May 12, 20222022/0142986HIGH DOSAGE TEBIPENEM PIVOXIL TABLET FORMULATIONPharmaceuticalsSPERO THERAPEUTICS, INC. · patent 12,048,691 granted from it
Aug 12, 20212021/0246169COMPOUNDSPharmaceuticalsSPERO THERAPEUTICS, INC. · patent 11,459,357 granted from it
Jul 22, 20212021/0221848POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICSPharmaceuticalsSPERO THERAPEUTICS, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton SPRO · research, not advice